SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial

Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial


  • Org Study ID: RG1006206
  • Secondary ID: NCI-2019-08028,10439,P30CA015704
  • NCT ID: NCT04383743
  • NCT Alias:
  • Sponsor: University of Washington - Other
  • Source: University of Washington

Brief Summary

This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, adriamycin, and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and combination chemotherapy before surgery may work better in treating patients with these muscle invasive bladder cancer variants compared to chemotherapy alone.

Detailed Description


OUTLINE:

Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of weeks 0, 3, and
6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0,
2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also
receive pegfilgrastim subcutaneously (SC) on day 1 or 2 of weeks 0, 2, 4, and 6 in the
absence of disease progression or unacceptable toxicity. Patients then undergo standard of
care radical cystectomy.

After completion of study treatment, patients are followed up about 1 month after surgery and
then every 3-6 months for 2 years.

Overal Status Start Date Phase Study Type
Recruiting December 9, 2020 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Pathologic complete response rate

Primary Outcome 1 - Time Frame: At time of radical cystectomy

Condition:

  • Stage II Bladder Cancer AJCC v8
  • Stage IIIA Bladder Cancer AJCC v8

Eligibility

Criteria:
Inclusion Criteria:

- Participants must have histologically confirmed diagnosis of muscle invasive bladder
cancer (cT2-T4a, N0-N1, M0 clinical stage per American Joint Commission on Cancer
[AJCC]). Clinical node-positive (N1) patients are eligible provided the lymph nodes
(LNs) are confined to the true pelvis and are within the planned surgical LN
dissection template

- Histology must be either pure or predominant non-urothelial histology (noted on any
TURBT)

- Participants must be deemed eligible for cisplatin-based chemotherapy, radical
cystectomy (RC) and pelvic lymph node dissection (PLND) by urologist and medical
oncologist

- Patients must agree to undergo curative intent surgery

- TURBT that showed muscularis propria invasion should be within 12 weeks prior to
beginning study therapy. Patients must have available tumor tissue from either initial
or repeat TURBT, prior to starting study therapy. Archival tumor tissue sample of a
tumor lesion (TURBT specimen) should be provided and must contain muscle invasive
component, at least >= T2 tumor. Formalin-fixed, paraffin embedded (FFPE) tissue
blocks are preferred to slides. If submitting unstained cut slides, newly cut slides
should be submitted to the testing laboratory, preferably within 14 days from the date
slides are cut if possible. Patient must be willing to provide tumor tissue for
research

- Must have clinical non-metastatic bladder cancer (M0) determined by cross-sectional
computed tomography (CT) chest, abdomen and pelvis (CAP) imaging

- A male participant must agree to use a contraception during the treatment period and
for at least 180 days after the last dose of study treatment and refrain from donating
sperm during this period

- A female participant is eligible to participate if she is not pregnant , not
breastfeeding, and at least one of the following conditions applies:

- Not a woman of childbearing potential (WOCBP) OR

- A WOCBP who agrees to follow the contraceptive guidance during the treatment
period and for at least 180 days after the last dose of study treatment

- The participant (or legally acceptable representative if applicable) provides written
informed consent for the trial

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Evaluation is to be performed within 7 days prior to the date of enrollment

- Absolute neutrophil count (ANC) >= 1500/uL (collected within 10 days prior to the
start of study treatment)

- Platelets >= 100 000/uL (collected within 10 days prior to the start of study
treatment)

- Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L (collected within 10 days prior to the start
of study treatment)

- Criteria must be met without erythropoietin dependency and without packed red
blood cell (pRBC) transfusion within last 2 weeks

- Serum creatinine =< 1.5 x upper limits of normal (ULN) OR calculated creatinine
clearance (glomerular filtration rate [GFR] can be used in place of creatinine or
creatinine clearance) >= 50 ml/min (collected within 10 days prior to the start of
study treatment). Measured or calculated creatinine clearance (GFR can be used in
place of creatinine clearance; 24-hour urine collection can be used for more accurate
estimate as needed)

- Creatinine clearance (CrCl) should be calculated per institutional standard

- Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total
bilirubin levels > 1.5 x ULN (collected within 10 days prior to the start of study
treatment)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x
ULN (collected within 10 days prior to the start of study treatment)

- International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN unless
participant is receiving anticoagulant therapy, as long as PT is within therapeutic
range of intended use of anticoagulants (collected within 10 days prior to the start
of study treatment)

- Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is
receiving anticoagulant therapy, as long as aPTT is within therapeutic range of
intended use of anticoagulants (collected within 10 days prior to the start of study
treatment)

Exclusion Criteria:

- A WOCBP who has a positive urine pregnancy test within 72 hours prior to enrollment.
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
test will be required

- Patients with pure small cell histology will be excluded. Mixed histology including
partial neuroendocrine small cell features will be permitted

- Patients considered to be medically unfit for accelerated (dose dense) MVAC
chemotherapy, TURBT or RC (per investigator discretion) will be excluded

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX 40, CD137)

- Has received prior systemic anti-cancer therapy including investigational agents
within 4 weeks. Intravesical therapies are allowed without specified treatment
interval

- Note: Participants must have recovered from all adverse events (AEs) due to
previous therapies to =< grade 1 or baseline. If participant had major surgery,
they must have recovered adequately from the toxicity and/or complications from
the intervention prior to starting study treatment

- Has received prior radiotherapy within 2 weeks of start of study treatment.
Participants must have recovered from all radiation-related toxicities, not require
corticosteroids, and should not have active radiation pneumonitis

- Has received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, a version of varicella/zoster (chicken pox), yellow fever, rabies,
Bacillus calmette-guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for
injection are generally killed virus vaccines and are allowed; however, intranasal
influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment

- Note: Participants who have entered the follow-up phase of an investigational
study may participate as long as it has been 4 weeks after the last dose of the
previous investigational agent

- Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in
dosing > 10 mg daily of prednisone dose equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug

- Has known additional malignancy that is progressing or has required active systemic
treatment within the past 2 years. Note: Participants with basal cell carcinoma or
squamous cell carcinoma of the skin, or any carcinoma in situ that have undergone
potentially curative therapy are not excluded. Low/intermediate risk prostate cancer
with prior potentially curative therapy, or no intent of future systemic therapy
and/or radiation is allowed. Non-invasive (Tis, Ta) upper urinary tract (renal
pelvis/ureter) is allowed. Urethra cancer with prior curative intent therapy with no
active recurrence is also allowed regardless of time elapsed

- Has known locally advanced (unresectable) or metastatic cancer on baseline
radiographic imaging (CT or magnetic resonance imaging [MRI]) obtained within 28 days
prior to study registration

- Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients

- Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment and is allowed. Note: Patients with active well controlled
type 1 diabetes mellitus, vitiligo, Graves' disease, Hashimoto disease, eczema, lichen
simplex chronicus, or psoriasis, not requiring systemic immunosuppression within the
past 2 years are not excluded

- Has history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis

- Has an active infection requiring systemic therapy

- Has known history of human immunodeficiency virus (HIV). Note: no HIV testing is
required

- Has known history of active hepatitis B (defined as hepatitis B surface antigen
[HBsAg] detected) or known active hepatitis C virus (defined as hepatitis C virus
[HCV] ribonucleic acid [RNA] [qualitative] detected) infection. Note: no testing for
hepatitis B and hepatitis C is required

- Has known history of active TB (Bacillus tuberculosis). Note: no testing is required
unless it is clinically indicated

- Has history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator

- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial

- Has had allogeneic solid visceral organ transplant
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Petros Grivas

Role: Principal Investigator

Affiliation: Fred Hutch/University of Washington Cancer Consortium

Overall Contact

Name: Petros Grivas

Phone: 206-606-7486

Email: pgrivas@uw.edu

Location

Facility Status Contact
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington 98109
United States
Recruiting Petros Grivas
206-606-7486
pgrivas@uw.edu